About Stryker Corporation
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Stryker Corporation (SYK) is a Healthcare company in the Medical Devices industry with a market capitalisation of $105.7B. The stock trades at 28.59x trailing earnings and yields 1.28%.
- Sector
- Healthcare
- Industry
- Medical Devices
- Market cap
- $105.7B
- P/E ratio
- 28.59
- Forward P/E
- 16.46
- EPS (TTM)
- $9.64
- Revenue (TTM)
- $25.8B
- Free cash flow
- $4.1B
- Profit margin
- 14.4%
- Dividend yield
- 1.28%
- Beta
- 0.77
- Shares outstanding
- 383.6M
Financial health: Strong8.6/10
8 strengths, 0 concerns. No red flags against these benchmarks.
- Debt to equity: 0.71 (Watch, benchmark < 0.5) — Debt of 0.71x equity is moderate against the 0.5x benchmark. It has been broadly flat over the last 4 years.
- Net debt vs cash flow: 2.7y (Strong, benchmark < 4 years) — Net debt of $11.8B is 2.7x annual free cash flow — about 3 years of cash flow to repay.
- Current ratio: 1.89 (Strong, benchmark > 1.5) — Short-term assets cover 1.89x short-term liabilities, against Graham's 1.5x floor. It has improved over the last 4 years.
- Return on equity: 16.5% (Strong, benchmark > 15%) — Earns 16.5% on shareholder equity, comfortably past the > 15% mark.
- Gross margin: 65.6% (Strong, benchmark > 40%) — Keeps 65.6% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 14.4% (Strong, benchmark > 10%) — Turns 14.4% of revenue into profit, comfortably past the > 10% mark.
- Free cash flow: $4.3B (Strong, benchmark positive) — Generated $4.3B of free cash flow after capital spending. It has improved over the last 4 years.
- Revenue growth: 9.4% (Watch, benchmark > 10%) — Revenue changed 9.4% year on year, short of the > 10% mark.
- Earnings growth: 44.1% (Strong, benchmark > 10%) — Earnings changed 44.1% year on year, comfortably past the > 10% mark.
- PEG ratio: 1.17 (Watch, benchmark < 1) — At 1.17, the price looks fair relative to expected growth — Lynch treated 1.0 as fair value.
- Payout ratio: 36.1% (Strong, benchmark < 60%) — Pays out 36.1% of earnings as dividends, leaving room to keep paying.